AlphAIalphai — Financial news for AI agents
prnewswire.comAUG 136 min read$HIT

Health In Tech Reports Second Quarter 2026 Financial Results

Health In Tech (Nasdaq: HIT) reported Q2 2026 revenue of $8.1M versus $9.3M in Q2 2025, and first-half 2026 revenue of $16.8M versus $17.3M. Contracted revenue was $32.3M as of June 30, 2026, and pipeline revenue was $66.3M as of July 31, 2026. Net loss was $2.5M. The company reaffirmed 2026 revenue guidance of $45M to $50M.

Original reporting
prnewswire.com
Published Aug 13, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 9:13 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Health In Tech Reports Second Quarter 2026 Financial Results — source image
Source · prnewswire.com
Decision brief

The 30-second read

$HITNeutralMed
01

Why it matters

The company’s Q2 and first-half results include a reaffirmed 2026 revenue outlook and a quantified pipeline conversion framework that translates quoting/binding status into expected contracted and GAAP revenue in 2026 and 2027.

02

Market read

Traders can use the reaffirmed guidance and the pipeline conversion math to reassess forward revenue recognition and the credibility of the company’s growth engine.

03

What to watch

Contracted Revenue recognition timing (GAAP straight-line over policy terms) can create quarter-to-quarter GAAP noise, so traders may overreact to GAAP revenue while underweighting contracted-book growth and PPPV trends.

Relevance 8/10Novelty 7/10Timing: after-hours results release, Aug. 13, 2026

Background

Health In Tech is an AI-enabled InsurTech platform focused on self-funded health plan stop-loss quoting and placement, using metrics like Contracted Revenue and Pipeline Revenue to describe forward revenue visibility.

Company-level read

Ticker impact

$HITNeutralMedium confidence
Context

Health In Tech reported Q2 2026 revenue of $8.1M, reaffirmed 2026 revenue guidance of $45M to $50M, and detailed pipeline conversion assumptions.

Expected impact

Likely modest post-release volatility, with upside bias if investors focus on pipeline conversion math and contracted-book growth, downside if they fixate on revenue decline and widening losses.

Evidence & confidence

This is a company-specific financial results PR with explicit guidance and forward revenue recognition ranges tied to pipeline conversion (15% to 40%). However, the article does not include consensus comparisons or a new guidance change, and revenue/losses show deterioration versus prior-year periods.

Market effects

Sector

Adds datapoints on AI-enabled InsurTech underwriting distribution metrics (brokers/TPAs/agency growth, contracted vs pipeline revenue) that may influence how investors underwrite similar platform models.

Regional

No clear regional spillover beyond US-listed InsurTech sentiment.

Global

Limited global relevance; primarily affects US small-cap growth/InsurTech risk appetite.

Counterpoint

What could challenge this read

Investors may discount the pipeline-to-contracted conversion range as optimistic, given Q2 revenue declined year over year and Adjusted EBITDA remains negative.

Key entities

  • company
    Health In Tech, Inc.

    Nasdaq-listed AI-enabled InsurTech platform reporting Q2 2026 results, pipeline metrics, and reaffirmed 2026 revenue guidance.

  • person
    Tim Johnson

    CEO who discussed contracted-book growth, a three-year rate stabilization program milestone, and the planned HitRix marketplace launch in 2H 2026.

Read at source← All news

Related articles

JUL 28
$HITMed

L&T, Hitachi Energy consortium signs Rs 15,000 crore+ framework pact with TenneT for offshore renewable project

According to L&T, it and Hitachi Energy formed a consortium with TenneT to sign a framework pact worth over Rs 15,000 crore for offshore renewable integration under TenneT’s 2 GW HVDC programme. L&T will handle EPC for converter platforms and infrastructure, while Hitachi Energy will supply HVDC Light. The scope covers four projects totaling 8 GW transmission capacity in the Netherlands and Germany.

financialexpress.com4 min
MAY 26
$HITMedAI 8/10

Sensex Today | Stock Market Live: Sensex, Nifty trade marginally higher; Adani Power, Hitachi Energy, Vedanta most active

Indian benchmarks Sensex and Nifty were marginally higher, with Adani Power, Hitachi Energy and Vedanta among the most active. The report also cites company updates: ONGC selected a BP Plc subsidiary as a technical service provider for the WO basin, with estimated production gains and a fixed fee plus revenue-linked service fees. Venus Pipes & Tubes began commercial operations of a fittings facility and added 4,200 MTPA seamless capacity (total 6,000 MTPA).

moneycontrol.com7 min
AUG 13
$STNEMed

Why is StoneCo stock sliding today?

StoneCo Ltd shares fell 2% in after-hours after its Q2 2026 results beat adjusted EPS but missed revenue. Adjusted EPS was R$2.40, in line with consensus, while revenue was R$3.59B vs R$3.67B expected. Adjusted net income fell 2.6% YoY to R$582.7M. Investors cited a 107.5% YoY jump in its credit portfolio and concerns tied to Brazil’s high rates.

investing.com4 min
AUG 13
$ETONHighAI 9/10

Why is Eton Pharmaceuticals stock surging today?

Eton Pharmaceuticals shares rose about 20% in after-hours after it reported Q2 2026 results. Revenue nearly doubled to $37.6M versus $26.88M consensus, and adjusted EPS was $0.43 versus $0.15 estimate. The company raised full-year 2026 revenue guidance to over $145M. Adjusted EBITDA increased to $16.2M, and H.C. Wainwright lifted its price target to $65 from $57.

investing.com4 min
AUG 13
$HTFLHighAI 9/10

Why is Heartflow stock surging today?

Investing.com reports Heartflow (HTFL) shares rose 16.1% in after-hours to $36 after its Q2 results beat expectations. Adjusted loss per share was -$0.07 vs -$0.19 consensus. Revenue was $64.1M, up 48% YoY. Full-year 2026 revenue guidance was raised to $246M-$250M. CEO John Farquhar sold 22,562 shares under a Rule 10b5-1 plan.

investing.com4 min